Attovia Therapeutics
David Bellovin is currently the Vice President, Discovery and Translational Biology at Attovia Therapeutics. Prior to this role, David held various positions at Alamar Biosciences, Inc., Zai Lab, and Five Prime Therapeutics, Inc., focusing on oncology discovery, in vivo pharmacology, and anti-cancer therapeutics. Their extensive experience includes working at Stanford University School of Medicine as an Instructor and Postdoctoral Fellow, where David researched liver cancer metastasis and developed novel mouse models. David has a Ph.D. in Experimental Pathology/Cancer Biology from Harvard Medical School and B.S. in Biochemistry, Molecular and Cellular Biology from the University of Arizona.
Attovia Therapeutics
Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into bispecifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches. By utilizing our ATTOBODY technology, we will develop novel medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We envision a world where no patient is left behind.